Cooley advised client Mirum Pharmaceuticals on its $210 million financing arrangement with Oberland Capital Management, as well as its $75 million follow-on public offering of 3,750,000 shares of common stock just days apart. Michael Tollini led the Cooley team advising Mirum on the revenue interest financing, which also included Addison Pierce, William Coombs, along with Sunny Chang, who provided life sciences expertise, and Eileen Marshall, who provided tax expertise. Jason Kent led the team advising on the follow-on public offering, which also included Alexa Ekman, Arielle Friehling and Jessica Wade. Mirum, whose securities trade on the Nasdaq Global Market as "MIRM," is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases.